Bionomics Stock price Australian S.E.

Equities

BNO

AU000000BNO5

Biotechnology & Medical Research

Delayed Australian S.E. 02:10:06 2023-08-24 am EDT 5-day change 1st Jan Change
0.01 AUD -.--% Intraday chart for Bionomics -.--% -.--%
Sales 2024 * 5.09M 3.31M Sales 2025 * 5.09M 3.31M Capitalization 16.88M 10.99M
Net income 2024 * -38M -24.75M Net income 2025 * -47M -30.61M EV / Sales 2024 * 3.32 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.32 x
P/E ratio 2024 *
-0.43 x
P/E ratio 2025 *
-0.28 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder CI
Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data MT
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap MT
Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023 CI
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2% DJ
Bionomics to Advance Social Anxiety Disorder Treatment Into Phase 3 Studies After End-of-Phase 2 Meeting With US FDA MT
Bionomics Limited Announces Successful and Favorable Outcomes of an End-Of-Phase 2 Meeting Meeting with the U.S. Food and Drug Administration CI
Bionomics Trades 1.8% Lower in Premarket Activity Tuesday After Surging 46% in Previous Regular Trading Session MT
Top Premarket Gainers MT
Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Bionomics Retreats 15% Premarket Friday After Surging 244% in Previous Trading Session Following Positive Phase 2b Data MT
Bionomics Sinks 12% After Hours Thursday Following 244% Surge in Previous Regular Trading Session on Positive Phase 2b Trial Results MT
Sector Update: Health Care Stocks Rising in Late Afternoon Trading MT
Top Midday Gainers MT
More news
1 year
0.01
Extreme 0.009
0.03
3 years
0.01
Extreme 0.009
0.27
5 years
0.01
Extreme 0.009
0.49
10 years
0.01
Extreme 0.009
0.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 23-01-04
Director of Finance/CFO 62 23-06-30
Chief Tech/Sci/R&D Officer - 23-06-30
Members of the board TitleAgeSince
Director/Board Member 61 16-06-15
Chairman 71 16-08-31
Director/Board Member 65 20-09-30
More insiders
Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.579 AUD
Average target price
19.9 AUD
Spread / Average Target
+1,160.23%
Consensus
  1. Stock
  2. Equities
  3. Stock Bionomics Limited
  4. Stock Bionomics - Australian S.E.